Jinli Wang1, Hongyang Zhao1, Fenfen Xu1, Piaopiao Zhang2, Yuan Zheng1, Nan Jia3. 1. Department of Pediatrics, Jinan Central Hospital Affiliated to Shandong University, Jinan, China. 2. Graduate School of Taishan Medical University, Tai'an, China. 3. Department of Neonatal, The Second Affiliated Hospital of Xi'an Medical College, No. 167, Textile City East Street, Baqiao District, Xi'an, 710038, Shanxi, China. NanJiasdf@163.com.
Abstract
BACKGROUND: Cystic pulmonary fibrosis (CF) affects mostly the lung of the newborns. Chronic infection and inflammation become the major causes of morbidity and mortality in CF. However, the underlying molecular mechanisms causing CF still remain unclear. METHODS: ELISA assay was used to examine the expression of HE4 and pro-inflammatory cytokines in W126VA4 cells supernatant fluid. qRT-PCR was applicable to determine the mRNA level of HE4, α-SMA, collagen 1, MMP2, MMP9 and various interleukins. Immunofluorescent assay was used to test the expression of HE4 in WI-26 VA4 cells. Major elements of MAPK and NF-κB signals pathways were examined by western blot. RESULTS: We found higher expression of HE4 in CF patients serum and lung biopsy. Interestingly, HE4 expression was positively correlated with fibrosis markers expression. In addition,HE4 overexpression increased inflammatory cytokines secretion and fibrosis markers expression in WI-26 VA4 cells. And NF-κB pathways were responsible for elevated inflammation. In addition, HE4/MAPK/MMPs signaling cascades destroyed the normal extracellular matrix (ECM) and promoted fibrosis. CONCLUSIONS: Overall, we first identified that HE4 promoted CF-associated inflammation. Additionally, NF-κB and MAPK signalings were further validated to be responsible for CF-associated inflammation and ECM destruction. Characterization of lumacaftor/ivacaftor in CF-associated inflammation may provide a novel insight into clinical CF treatment.
BACKGROUND:Cystic pulmonary fibrosis (CF) affects mostly the lung of the newborns. Chronic infection and inflammation become the major causes of morbidity and mortality in CF. However, the underlying molecular mechanisms causing CF still remain unclear. METHODS: ELISA assay was used to examine the expression of HE4 and pro-inflammatory cytokines in W126VA4 cells supernatant fluid. qRT-PCR was applicable to determine the mRNA level of HE4, α-SMA, collagen 1, MMP2, MMP9 and various interleukins. Immunofluorescent assay was used to test the expression of HE4 in WI-26 VA4 cells. Major elements of MAPK and NF-κB signals pathways were examined by western blot. RESULTS: We found higher expression of HE4 in CF patients serum and lung biopsy. Interestingly, HE4 expression was positively correlated with fibrosis markers expression. In addition,HE4 overexpression increased inflammatory cytokines secretion and fibrosis markers expression in WI-26 VA4 cells. And NF-κB pathways were responsible for elevated inflammation. In addition, HE4/MAPK/MMPs signaling cascades destroyed the normal extracellular matrix (ECM) and promoted fibrosis. CONCLUSIONS: Overall, we first identified that HE4 promoted CF-associated inflammation. Additionally, NF-κB and MAPK signalings were further validated to be responsible for CF-associated inflammation and ECM destruction. Characterization of lumacaftor/ivacaftor in CF-associated inflammation may provide a novel insight into clinical CF treatment.
Entities:
Keywords:
Cystic fibrosis transmembrane conductance regulator (CFTR); Cystic pulmonary fibrosis (CF); Human epididymis protein 4 (HE4); MMP2; MMP9; NF-κB pathways
Authors: Béla Nagy; Béla Nagy; Libor Fila; Luka A Clarke; Ferenc Gönczy; Olga Bede; Dóra Nagy; Rita Újhelyi; Ágnes Szabó; Andrea Anghelyi; Miklós Major; Zsolt Bene; Zsolt Fejes; Péter Antal-Szalmás; Harjit Pal Bhattoa; György Balla; János Kappelmayer; Margarida D Amaral; Milan Macek; István Balogh Journal: Chest Date: 2016-04-19 Impact factor: 9.410
Authors: Simon Y Graeber; Christian Dopfer; Lutz Naehrlich; Lena Gyulumyan; Heike Scheuermann; Stephanie Hirtz; Sabine Wege; Heimo Mairbäurl; Marie Dorda; Rebecca Hyde; Azadeh Bagheri-Hanson; Claudia Rueckes-Nilges; Sebastian Fischer; Marcus A Mall; Burkhard Tümmler Journal: Am J Respir Crit Care Med Date: 2018-06-01 Impact factor: 21.405
Authors: Xiao Xiao Tang; Lynda S Ostedgaard; Mark J Hoegger; Thomas O Moninger; Philip H Karp; James D McMenimen; Biswa Choudhury; Ajit Varki; David A Stoltz; Michael J Welsh Journal: J Clin Invest Date: 2016-01-25 Impact factor: 14.808
Authors: Vanina G Da Ros; Mariana Weigel Muñoz; Maria A Battistone; Nicolás G Brukman; Guillermo Carvajal; Ludmila Curci; MatIas D Gómez-ElIas; D Bora J Cohen; Patricia S Cuasnicu Journal: Asian J Androl Date: 2015 Sep-Oct Impact factor: 3.285